TY  - GEN
AU  - Hillner,B E
TI  - Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma
SN  - 0959-8049
PY  - 1998///1216
KW  - Antineoplastic Agents
KW  - economics
KW  - Cohort Studies
KW  - Combined Modality Therapy
KW  - Cost-Benefit Analysis
KW  - Disease-Free Survival
KW  - Health Care Costs
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Melanoma
KW  - therapy
KW  - Middle Aged
KW  - Recombinant Proteins
KW  - Skin Neoplasms
KW  - Survival Rate
KW  - Virginia
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1016/s0959-8049(98)00002-1
ER  -